No annual revenue total was found in OS THERAPIES INCORPORATED's SEC filings.
Os Therapies Incorporated (OSTX) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$14.7 million.
Revenue
—
Net income (TTM)
$-39.37M
-175.7% vs year-ago TTM
Operating cash flow (TTM)
$-18.53M
-60.3% vs year-ago TTM
Free cash flow
$-14.70M
EPS (TTM)
$-1.06
Dividend per share
None
Shares outstanding
39.53M
+82.5% vs prior year
Net cash
—
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- OSTX (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Rockville, MD
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1795091
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
|---|---|---|
| Operating income | -$28.7M | -$6.8M |
| Net income | -$28.8M | -$8.9M |
| Diluted EPS | -$0.98 | -$1.28 |
| Operating cash flow | -$14.2M | -$7.3M |
| Free cash flow | -$14.7M | — |
| Total assets | $6.8M | $5.5M |
| Total liabilities | $11.9M | $4.7M |
| Stockholders' equity | -$6.1M | -$3.3M |
| Cash and investments | $269,830 | $5.5M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Unregistered share sale, Other events
|
Oct 19, 2026 | Oct 15, 2026 |
| 8-K |
Current report
Material agreement, Officer or director change, Other events
|
Oct 5, 2026 | Sep 29, 2026 |
| 8-K |
Current report
Other events
|
Sep 10, 2026 | Sep 10, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Sep 9, 2026 | Sep 9, 2026 |
| 8-K |
Current report
Material agreement
|
Aug 21, 2026 | Aug 21, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
All 243 Os Therapies Incorporated SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.